Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,666 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High Dose Drug A Clear all

Conditions: Phenylketonuria
Interventions: SYNB1934v1, Placebo; Drug
Lead sponsor: Synlogic; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 14
States / cities: Culver City, California • Orange, California • Palo Alto, California + 11 more

Conditions: DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, DLBCL Arising From Follicular Lymphoma
Interventions: E7777, Fludarabine, Cyclophosphamide, Tisagenlecleucel, Axicabtagene Ciloleucel, Lisocabtagene Maraleucel Intravenous Suspension; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Nonsegmental Vitiligo
Interventions: Zasocitinib, Placebo; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 21
States / cities: Bryant, Arkansas • Fountain Valley, California • Fremont, California + 16 more

Conditions: Pain
Interventions: Ropivacaine 0.1%, Ropivacaine 0.2%, Normal saline, On-Q ® elastomeric pump; Drug · Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Ataxia Telangiectasia, Genetic Syndrome
Interventions: EryDex System; Combination Product
Lead sponsor: Quince Therapeutics S.p.A.; Industry
Eligibility: 6 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Cincinnati, Ohio + 1 more

Conditions: Healthy Volunteers
Interventions: TAK-648 Tablet, TAK-648 Oral Solution; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hyperkalemia
Interventions: RDX013, Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: Coral Gables, Florida • Miami Lakes, Florida • Miami Springs, Florida + 3 more

Conditions: Post-op Pain
Interventions: Morphine PCA started at the end of surgery, 1 Percocet 1/325mg every 4 hours; may receive a second Percocet if needed., For the 30ml ropivacaine the intervention would be the subject can request extra pain medication which would be Percocet and/or morphine PCA.; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Type 1 Diabetes
Interventions: Metformin, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 25 Years to 59 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Alcohol Use Disorder
Interventions: ANS-6637 Low Dose, ANS-6637 High Dose, Matched Placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV Infections
Interventions: CPT31, Placebo; Drug
Lead sponsor: Navigen, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma
Interventions: NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib, Carboplatin, Paclitaxel, FOLFIRI Protocol, Bevacizumab; Drug
Lead sponsor: Neonc Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Beverly Hills, California • Glendale, California • Los Angeles, California + 5 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: SL-172154, Azacitidine (AZA), Venetoclax; Drug
Lead sponsor: Shattuck Labs, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 16
States / cities: Duarte, California • Los Angeles, California • New Haven, Connecticut + 13 more

Conditions: Idiopathic Membranous Nephropathy
Interventions: Rituximab, Cyclosporine; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 18
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 13 more

Conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Interventions: GVAX, Placebo Vaccine, Allogeneic Hematopoietic Stem Cell Transplant, Busulfan, Fludarabine, Tacrolimus, Methotrexate; Biological · Procedure · Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 4
States / cities: Boston, Massachusetts

Conditions: Weight Management
Interventions: GS-4571, Placebo, Omeprazole; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Miami, Florida • San Antonio, Texas • Salt Lake City, Utah

Conditions: Cigarette Smoking-Related Carcinoma
Interventions: Bupropion Hydrochloride Controlled-release, Nicotine Replacement, Questionnaire Administration, Tobacco Cessation Counseling, Varenicline; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 2,010 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Heart Failure, Cardiac Failure, Acute Decompensated Heart Failure (ADHF)
Interventions: Isolated veno-venous ultrafiltration (AQ), IV Loop Diuretics (LD); Device · Drug
Lead sponsor: Nuwellis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 38
States / cities: Huntsville, Alabama • Scottsdale, Arizona • Los Angeles, California + 28 more

Conditions: HIV, Prophylaxis, Transgender
Interventions: Truvada alone, Truvada plus Leuprolide 11.25mg intramuscular injection, Truvada plus Estradiol 1 mg, Truvada plus Estradiol 6 mg, Estradiol 6 mg alone; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ
Interventions: filgrastim, gene therapy, lomustine, procarbazine hydrochloride, vincristine sulfate, in vitro-treated peripheral blood stem cell transplantation; Procedure · Biological · Drug
Lead sponsor: Indiana University; Other
Eligibility: 5 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 2
States / cities: Indianapolis, Indiana • Boston, Massachusetts

Conditions: Schizophrenia
Interventions: SPD489 low dose range (40mg, 80mg, and 100mg), SPD489 high dose range (120mg, 140mg and 160mg), Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 4
States / cities: Miami Springs, Florida • O'Fallon, Missouri • Saint Charles, Missouri + 1 more

Conditions: Pmm2-CDG, Phosphomannomutase 2 Deficiency, Phosphomannomutase 2 Congenital Disorder of Glycosylation, Phosphomannomutase II Congenital Disorder of Glycosylation, Phosphomannomutase II Deficiency
Interventions: Epalrestat, Placebo; Drug
Lead sponsor: Maggie's Pearl, LLC; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions: CPI-1205, Cobicistat, Enzalutamide, Abiraterone, Prednisone; Drug
Lead sponsor: Constellation Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 41
States / cities: Anchorage, Alaska • Beverly Hills, California • Duarte, California + 34 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: Bemcentinib, Cytarabine, Decitabine; Drug
Lead sponsor: BerGenBio ASA; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 2
States / cities: Iowa City, Iowa • Houston, Texas

Search by objective public record fields.

Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3)

Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL

A Study of Zasocitinib in Adults With Nonsegmental Vitiligo

Use of On-Q Pump for Pain Post C-Section

Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study

A Study to Assess the Relative Bioavailability and to Assess the Effect of Food on the Bioavailability of a TAK-648 Tablet in Healthy Participants

A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia

Adductor Canal Nerve Block Following Total Knee Arthroplasty

Effect of Metformin on Vascular and Mitochondrial Function in Type 1 Diabetes

Development of a Selective ALDH2 Inhibitor to Treat AUD

A Clinical Study of the HIV Drug CPT31 in Healthy Volunteers

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

MEmbranous Nephropathy Trial Of Rituximab

GVAX vs. Placebo for MDS/AML After Allo HSCT

Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)

Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial

Study of Heart Failure Hospitalizations After Aquapheresis Therapy Compared to Intravenous (IV) Diuretic Treatment

Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW

Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors

SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia

Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS